| 7.96 0.81 (11.33%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.99 |
1-year : | 11.67 |
| Resists | First : | 8.56 |
Second : | 9.99 |
| Pivot price | 7.4 |
|||
| Supports | First : | 7.66 |
Second : | 7.11 |
| MAs | MA(5) : | 7.4 |
MA(20) : | 7.45 |
| MA(100) : | 7.85  |
MA(250) : | 9.85 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 25.2 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 19 | Low : | 6.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GYRE ] has closed It is unclear right now based on current values. 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.51 - 8.57 | 8.57 - 8.61 |
| Low: | 7.65 - 7.7 | 7.7 - 7.75 |
| Close: | 7.88 - 7.97 | 7.97 - 8.05 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Fri, 10 Oct 2025
Real time breakdown of Gyre Therapeutics Inc. stock performance - Risk Management & Technical Pattern Alert System - newser.com
Fri, 10 Oct 2025
Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Fri, 10 Oct 2025
Visual trend scoring systems applied to Gyre Therapeutics Inc. - 2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Fri, 10 Oct 2025
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Fri, 10 Oct 2025
Gyre Therapeutics initiated with a Buy at Jefferies - TipRanks
Fri, 10 Oct 2025
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 87.1 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,770 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 4 % |
| Operating Margin | 8.1 % |
| Return on Assets (ttm) | 4.2 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 1.12 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | -62.8 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 398 |
| PEG Ratio | 0 |
| Price to Book value | 7.88 |
| Price to Sales | 7.07 |
| Price to Cash Flow | 779.94 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 45.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|